KIORA PHARMACEUTICALS INC (KPRX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$11.0M
Cash & Equivalents
$3.2M
Quarterly Burn Rate
10 mo
Est. Cash Runway
$11M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-11-01 | Phase2 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06825702 | Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema | PHASE2 | Recruiting | 28 |
| NCT06628947 | A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa | PHASE2 | Recruiting | 36 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.